Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Current trends in large cell lymphoma

Leukemia volume 17, pages 1948–1960 (2003)Cite this article

Abstract

For the last decade, cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) has been the best available standard of care for aggressive non-Hodgkin's lymphoma (NHL), based on equivalent therapeutic results with other multiagent chemotherapy accompanied by lower costs and lesser toxicity. However, only 40–45% of these patients are cured with CHOP. New treatment strategies have been employed, including the addition of Rituximab to CHOP in elderly patients; dose escalation using granulocyte-colony-stimulating factor; overcoming the multidrug resistance phenotype with infusional chemotherapeutic regimens and use of some newer agents. Furthermore, the International Prognostic Factor index (IPI) has permitted identification of subsets of patients with large variations in prognosis, allowing prognosis specific therapy to be tested. There is now accumulating evidence that the clinical behavior of certain NHL can be profiled by the expression of certain molecular markers, which will undoubtedly play a role in the development of new prognostic models that may refine our ability to identify poor-risk patients. Regardless, there is still significant opportunity for improving survival in large cell lymphomas.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392.

    CAS  PubMed  Google Scholar 

  2. Anonymous. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project. Cancer 1982; 49: 2112–2135.

  3. Anonymous. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89: 3909–3918.

  4. Jaffe ES, Harris NL, Diebold J, Muller-Hermelink HK . World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. A progress report. Am J Clin Pathol 1999; 111: S8–S12.

    CAS  PubMed  Google Scholar 

  5. Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419–1432.

    Article  CAS  PubMed  Google Scholar 

  6. Jaffe ES, Harris NL, Stein H, Vardiman JW World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Haematopoetic and Lymphoid Tissues. Lyon, France: IARC Press, 2001.

    Google Scholar 

  7. Doggett RS, Wood GS, Horning S, Levy R, Dorfman RF, Bindl J et al. The immunologic characterization of 95 nodal and extranodal diffuse large cell lymphomas in 89 patients. Am J Pathol 1984; 115: 245–252.

    CAS  PubMed  PubMed Central  Google Scholar 

  8. Stein H, Lennert K, Feller AC, Mason DY . Immunohistological analysis of human lymphoma: correlation of histological and immunological categories. Adv Cancer Res 1984; 42: 67–147.

    Article  CAS  PubMed  Google Scholar 

  9. van Besien K, Kelta M, Bahaguna P . Primary mediastinal B-cell lymphoma: a review of pathology and management. J Clin Oncol 2001; 19: 1855–1864.

    Article  CAS  PubMed  Google Scholar 

  10. Jacobson JO, Aisenberg AC, Lamarre L, Willett CG, Linggood RM, Miketic LM et al. Mediastinal large cell lymphoma. An uncommon subset of adult lymphoma curable with combined modality therapy. Cancer 1988; 62: 1893–1898.

    Article  CAS  PubMed  Google Scholar 

  11. Lazzarino M, Orlandi E, Paulli M, Strater J, Klersy C, Gianelli U et al. Treatment outcome and prognostic factors for primary mediastinal (thymic) B-cell lymphoma: a multicenter study of 106 patients. J Clin Oncol 1997; 15: 1646–1653.

    Article  CAS  PubMed  Google Scholar 

  12. Nguyen LN, Ha CS, Hess M, Romaguera JE, Manning JT, Cabanillas F et al. The outcome of combined-modality treatments for stage I and II primary large B-cell lymphoma of the mediastinum. Int J Radiat Oncol Biol Phys 2000; 47: 1281–1285.

    Article  CAS  PubMed  Google Scholar 

  13. Ferry JA, Harris NL, Picker LJ, Weinberg DS, Rosales RK, Tapia J et al. Intravascular lymphomatosis (malignant angioendotheliomatosis). A B-cell neoplasm expressing surface homing receptors. Mod Pathol 1988; 1: 444–452.

    CAS  PubMed  Google Scholar 

  14. DiGiuseppe JA, Nelson WG, Seifter EJ, Boitnott JK, Mann RB . Intravascular lymphomatosis: a clinicopathologic study of 10 cases and assessment of response to chemotherapy. J Clin Oncol 1994; 12: 2573–2579.

    Article  CAS  PubMed  Google Scholar 

  15. Klein U, Goossens T, Fischer M, Kanzler H, Braeuninger A, Rajewsky K et al. Somatic hypermutation in normal and transformed human B cells. Immunol Rev 1998; 162: 261–280.

    Article  CAS  PubMed  Google Scholar 

  16. Vaux DL, Cory S, Adams JM . Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. Nature 1988; 335: 440–442.

    Article  CAS  PubMed  Google Scholar 

  17. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S et al. Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 1991; 88: 8661–8665.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Korsmeyer SJ . BCL-2 gene family and the regulation of programmed cell death. Cancer Res 1999; 59: 1693s–1700s.

    CAS  PubMed  Google Scholar 

  19. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C et al. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA). Blood 1996; 87: 265–272.

    CAS  PubMed  Google Scholar 

  20. Lo Coco F, Ye BH, Lista F, Corradini P, Offit K, Knowles DM et al. Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma. Blood 1994; 83: 1757–1759.

    CAS  PubMed  Google Scholar 

  21. Ye BH, Lista F, Lo Coco F, Knowles DM, Offit K, Chaganti RS et al. Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large-cell lymphoma. Science 1993; 262: 747–750.

    Article  CAS  PubMed  Google Scholar 

  22. Chang CC, Ye BH, Chaganti RS, Dalla-Favera R . BCL-6, a POZ/zinc-finger protein, is a sequence-specific transcriptional repressor. Proc Natl Acad Sci USA 1996; 93: 6947–6952.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Dent AL, Shaffer AL, Yu X, Allman D, Staudt LM . Control of inflammation, cytokine expression, and germinal center formation by BCL-6. Science 1997; 276: 589–592.

    Article  CAS  PubMed  Google Scholar 

  24. Askew DS, Ashmun RA, Simmons BC, Cleveland JL . Constitutive c-myc expression in an IL-3-dependent myeloid cell line suppresses cell cycle arrest and accelerates apoptosis. Oncogene 1991; 6: 1915–1922.

    CAS  PubMed  Google Scholar 

  25. Koduru PR, Raju K, Vadmal V, Menezes G, Shah S, Susin M et al. Correlation between mutation in P53, p53 expression, cytogenetics, histologic type, and survival in patients with B-cell non-Hodgkin's lymphoma. Blood 1997; 90: 4078–4091.

    CAS  PubMed  Google Scholar 

  26. Ichikawa A, Kinoshita T, Watanabe T, Kato H, Nagai H, Tsushita K et al. Mutations of the p53 gene as a prognostic factor in aggressive B-cell lymphoma. N Engl J Med 1997; 337: 529–534.

    Article  CAS  PubMed  Google Scholar 

  27. Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000; 403: 503–511.

    Article  CAS  PubMed  Google Scholar 

  28. Huang JZ, Sanger WG, Greiner TC, Staudt LM, Weisenburger DD, Pickering DL et al. The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99: 2285–2290.

    Article  CAS  PubMed  Google Scholar 

  29. Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med 2002; 8: 68–74.

    Article  CAS  PubMed  Google Scholar 

  30. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947.

    Article  PubMed  Google Scholar 

  31. Anonymous. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994.

  32. Schein PS, Chabner BA, Canellos GP, Young RC, Berard C, DeVita VT . Potential for prolonged disease-free survival following combination chemotherapy of non-Hodgkin's lymphoma. Blood 1974; 43: 181–189.

    CAS  PubMed  Google Scholar 

  33. Kaminski MS, Coleman CN, Colby TV, Cox RS, Rosenberg SA . Factors predicting survival in adults with stage I and II large-cell lymphoma treated with primary radiation therapy. Ann Intern Med 1986; 104: 747–756.

    Article  CAS  PubMed  Google Scholar 

  34. Longo DL . Combined modality therapy for localized aggressive lymphoma: enough or too much? J Clin Oncol 1989; 7: 1179–1181.

    Article  CAS  PubMed  Google Scholar 

  35. Tondini C, Giardini R, Bozzetti F, Valagussa P, Santoro A, Bertulli R et al. Combined modality treatment for primary gastrointestinal non-Hodgkin's lymphoma: the Milan Cancer Institute experience. Ann Oncol 1993; 4: 831–837.

    Article  CAS  PubMed  Google Scholar 

  36. Armitage JO, Cheson BD . Interpretation of clinical trials in diffuse large-cell lymphoma. J Clin Oncol 1988; 6: 1335–1347.

    Article  CAS  PubMed  Google Scholar 

  37. Jones SE, Miller TP, Connors JM . Long-term follow-up and analysis for prognostic factors for patients with limited-stage diffuse large-cell lymphoma treated with initial chemotherapy with or without adjuvant radiotherapy. J Clin Oncol 1989; 7: 1186–1191.

    Article  CAS  PubMed  Google Scholar 

  38. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998; 339: 21–26.

    Article  CAS  PubMed  Google Scholar 

  39. Glick J, Kim K, Earle J, O'Connell M . An ECOG randomized phase III trial of CHOP vs CHOP+radiotherapy (XRT) for intermediate grade early stage non-Hodgkin's lymphoma (NHL). Proc Am Soc Clin Oncol 1995; 14: 391.

    Google Scholar 

  40. Miller TP, LeBlanc M, Spier CM . CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphoms: update of the Southwest Oncology Group (SWOG) randomized trial. Blood 2001; 98: 724a.

    Article  Google Scholar 

  41. Horning SJ, Glick J, Kim K . CHOP vCHOP=radiotherapy (RT) for limited-stage diffuse aggressive lymphoma. Blood 2001; 98: 724a.

    Google Scholar 

  42. Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006.

    Article  CAS  PubMed  Google Scholar 

  43. Messori A, Vaiani M, Trippoli S, Rigacci L, Jerkeman M, Longo G . Survival in patients with intermediate or high grade non-Hodgkin's lymphoma: meta-analysis of randomized studies comparing third generation regimens with CHOP. Br J Cancer 2001; 84: 303–307.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Gordon LI, Harrington D, Andersen J, Colgan J, Glick J, Neiman R et al. Comparison of a second-generation combination chemotherapeutic regimen (m-BACOD) with a standard regimen (CHOP) for advanced diffuse non-Hodgkin's lymphoma. N Engl J Med 1992; 327: 1342–1349.

    Article  CAS  PubMed  Google Scholar 

  45. Longo DL, DeVita VT, Duffey PL, Wesley MN, Ihde OC, Hubbard SM, Gilliom M, Jaffe ES, Cossman J and Fisher RI . Superiority of ProMACE-CytoBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol 1991; 9: 25–38.

    Article  CAS  PubMed  Google Scholar 

  46. Philip T, Guglielmi C, Hagenbeek A, Somers R, Van der Lelie H, Bron D et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma. N Engl J Med 1995; 333: 1540–1545.

    Article  CAS  PubMed  Google Scholar 

  47. Blay J, Gomez F, Sebban C, Bachelot T, Biron P, Guglielmi C et al. The International Prognostic Index correlates to survival in patients with aggressive lymphoma in relapse: analysis of the PARMA trial. Parma Group. Blood 1998; 92: 3562–3568.

    CAS  PubMed  Google Scholar 

  48. Nademanee A, Molina A, O'Donnell MR, Dagis A, Snyder DS, Parker P et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997; 90: 3844–3852.

    CAS  PubMed  Google Scholar 

  49. Gulati SC, Shank B, Black P, Yopp J, Koziner B, Straus D et al. Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988; 6: 1303–1313.

    Article  CAS  PubMed  Google Scholar 

  50. Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC et al. Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: a pilot study. J Clin Oncol 1993; 11: 931–936.

    Article  CAS  PubMed  Google Scholar 

  51. Pettengell R, Radford JA, Morgenstern GR, Scarffe JH, Harris M, Woll PJ et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin's lymphoma. J Clin Oncol 1996; 14: 586–592.

    Article  CAS  PubMed  Google Scholar 

  52. Cortelazzo S, Rossi A, Bellavita P, Oldani E, Viero P, Buelli M et al. Clinical outcome after autologous transplantation in non-Hodgkin's lymphoma patients with high International Prognostic Index (IPI). Ann Oncol 1999; 10: 427–432.

    Article  CAS  PubMed  Google Scholar 

  53. Haioun C, Lepage E, Gisselbrecht C, Coiffier B, Bosly A, Tilly H et al. Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin's lymphoma in first complete remission: a study of 464 patients. Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 1994; 12: 2543–2551.

    Article  CAS  PubMed  Google Scholar 

  54. Verdonck LF, van Putten WL, Hagenbeek A, Schouten HC, Sonneveld P, van Imhoff GW et al. Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin's lymphoma. N Engl J Med 1995; 332: 1045–1051.

    Article  CAS  PubMed  Google Scholar 

  55. Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a Groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000; 18: 3025–3030.

    Article  CAS  PubMed  Google Scholar 

  56. Gianni AM, Bregni M, Siena S, Brambilla C, Di Nicola M, Lombardi F et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997; 336: 1290–1297.

    Article  CAS  PubMed  Google Scholar 

  57. Santini G, Salvagno L, Leoni P, Chisesi T, De Souza C, Sertoli MR et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol 1998; 16: 2796–2802.

    Article  CAS  PubMed  Google Scholar 

  58. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, Bron D, Roozendaal KJ, Noordijk EM et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized phase III EORTC study. J Natl Cancer Inst 2001; 93: 22–30.

    Article  CAS  PubMed  Google Scholar 

  59. Gisselbrecht C, Lepage E, Molina T, Quesnel B, Fillet G, Lederlin P et al. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol 2002; 20: 2472–2479.

    Article  CAS  PubMed  Google Scholar 

  60. Kaiser U, Uebelacker I, Abel U, Birkmann J, Trumper L, Schmalenberg H et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for ‘aggressive’ lymphoma. J Clin Oncol 2002; 20: 4413–4419.

    Article  CAS  PubMed  Google Scholar 

  61. Gherlinzoni F, Martelli M, Tura S . Early autologous stem cell transplantation(ASCT) versus conventional first-line chemotherapy in high-risk aggressive non-Hodgkin's lymphomas (NHL): an Italian multicenter randomized trial. Blood 2000; 96 (Suppl. 1): 2069a.

    Google Scholar 

  62. Tilly H, Mounier N, Lederlin P, Briere J, Dupriez B, Sebban C et al. Randomized comparison of ACVBP and m-BACOD in the treatment of patients with low-risk aggressive lymphoma: the LNH87-1 study. Groupe d'Etudes des Lymphomes de l'Adulte. J Clin Oncol 2000; 18: 1309–1315.

    Article  CAS  PubMed  Google Scholar 

  63. Shipp MA, Abeloff MD, Antman KH, Carroll G, Hagenbeek A, Loeffler M et al. International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury. J Clin Oncol 1999; 17: 423–429.

    Article  CAS  PubMed  Google Scholar 

  64. Morrison VA, Peterson BA . High-dose therapy and transplantation in non-Hodgkin's lymphoma. Semin Oncol 1999; 26: 84–98.

    CAS  PubMed  Google Scholar 

  65. Johnston LJ, Horning SJ . Autologous hematopoietic cell transplantation in non-Hodgkin's lymphoma. Hematol Oncol Clin N Am 1999; 13: 889–918.

    Article  CAS  Google Scholar 

  66. Friedberg JW, Neuberg D, Stone RM, Alyea E, Jallow H, LaCasce A et al. Outcome in patients with myelodysplastic syndrome after autologous bone marrow transplantation for non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3128–3135.

    Article  CAS  PubMed  Google Scholar 

  67. Reff ME, Carner K, Chambers KS, Chinn PC, Leonard JE, Raab R et al. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20. Blood 1994; 83: 435–445.

    CAS  PubMed  Google Scholar 

  68. Maloney DG, Smith B, Appelbaum FR . The antitumor effect of monoclonal anti-CD20 antibody therapy includes direct anti-proliferative activity and induction of apoptosis in CD20 positive non-Hodgkin's lymphoma cell lines. Blood 1996; 83: 637a.

    Google Scholar 

  69. Maloney DG . Preclinical and phase I and II trials of Rituximab. Semin Oncol 1999; 26: 74–78.

    CAS  PubMed  Google Scholar 

  70. Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932.

    CAS  PubMed  Google Scholar 

  71. Winkler U, Schulz HR, Klein TO, Jensen M, Manzke O, Schmitz SH et al. Treatment of patients with mantle-cell and aggressive B-cell non-Hodgkin's lymphoma using the monoclonal anti-CD20 antibody Rituximab (Rituxan): evaluation of safety and response. Blood 1999; 94 (Suppl. 1): 270b.

    Google Scholar 

  72. Czuczman MS, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol 1999; 17: 268–276.

    Article  CAS  PubMed  Google Scholar 

  73. Vose JM, Link BK, Grossbard ML, Czuczman M, Grillo-Lopez A, Gilman P et al. Phase II study of Rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397.

    Article  CAS  PubMed  Google Scholar 

  74. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R et al. CHOP chemotherapy plus Rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242.

    Article  CAS  PubMed  Google Scholar 

  75. Mounier N, Briere J, Gisselbrecht C, Emile JF, Lederlin P, Sebban C et al. Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). Blood 2003; 101: 4279–4284.

    Article  CAS  PubMed  Google Scholar 

  76. Leonard JP, Coleman M, Chadburn A, Matthews JC, Bayer R, Schuster MW et al. Epratuzumab (hLL2, anti-CD22 humanized monoclonal antibody) is an active and well-tolerated therapy for refractory/relapsed diffuse large B-cell non-Hodgkin's lymphoma(NHL). Blood 2000; 96 (Suppl. 1): 578a.

    Google Scholar 

  77. Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM . 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma. J Nucl Med 2003; 44: 77–84.

    CAS  PubMed  Google Scholar 

  78. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin's lymphoma. J Clin Oncol 1998; 16: 3246–3256.

    Article  CAS  PubMed  Google Scholar 

  79. Kaminski MS, Zasadny KR, Francis IR, Milik AW, Ross CW, Moon SD et al. Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody. N Engl J Med 1993; 329: 459–465.

    Article  CAS  PubMed  Google Scholar 

  80. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M et al. Radioimmunotherapy with iodine (131)I Tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience. Blood 2000; 96: 1259–1266.

    CAS  PubMed  Google Scholar 

  81. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3793–3803.

    Article  CAS  PubMed  Google Scholar 

  82. Wilson WH, Little R, Pearson D, Jaffe ES, Steinberg SM, Cheson BD et al. Phase II and dose-escalation with or without granulocyte colony-stimulating factor study of 9-aminocamptothecin in relapsed and refractory lymphomas. J Clin Oncol 1998; 16: 2345–2351.

    Article  CAS  PubMed  Google Scholar 

  83. Rosen LS . Irinotecan in lymphoma, leukemia, and breast, pancreatic, ovarian, and small-cell lung cancers. Oncology (Huntingt) 1998; 12: 103–109.

    CAS  Google Scholar 

  84. Sarris AH, Phan A, Goy A, Romaguera J, Hagemeister FB, Rodriguez MA et al. Irinotecan in relapsed or refractory non-Hodgkin's lymphomas. Indications of activity in a phase II trial. Oncology (Huntingt) 2002; 16: 27–31.

    CAS  Google Scholar 

  85. Niitsu N, Iijima K, Chizuka A . Combination therapy with irinotecan (CPT-11), mitoxantrone, and dexamethasone in relapsed or refractory non-Hodgkin's lymphoma: a pilot study. Ann Hematol 2001; 80: 411–416.

    Article  CAS  PubMed  Google Scholar 

  86. Bass AJ, Gockerman JP, Hammett E, DeCastro CM, Adams DJ, Rosner GL et al. Phase I evaluation of prolonged-infusion gemcitabine with irinotecan for relapsed or refractory leukemia or lymphoma. J Clin Oncol 2002; 20: 2995–3000.

    Article  CAS  PubMed  Google Scholar 

  87. Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786–3792.

    Article  CAS  PubMed  Google Scholar 

  88. Savage DG, Rule SA, Tighe M, Garrett TJ, Oster MW, Lee RT et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11: 595–597.

    Article  CAS  PubMed  Google Scholar 

  89. Zhu XH, Shen YL, Jing YK, Cai X, Jia PM, Huang Y et al. Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations. J Natl Cancer Inst 1999; 91: 772–778.

    Article  CAS  PubMed  Google Scholar 

  90. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999; 59: 2615–2622.

    CAS  PubMed  Google Scholar 

  91. Shipp MA, Neuberg D, Janicek M, Canellos GP, Shulman LN . High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916–2923.

    Article  CAS  PubMed  Google Scholar 

  92. Bartlett NL, Petroni GR, Parker BA, Wagner ND, Gockerman JP, Omura GA et al. Dose-escalated cyclophosphamide, doxorubicin, vincristine, prednisone, and etoposide (CHOPE) chemotherapy for patients with diffuse lymphoma: Cancer and Leukemia Group B studies 8852 and 8854. Cancer 2001; 92: 207–217.

    Article  CAS  PubMed  Google Scholar 

  93. Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncolgy Group (SWOG 9349). J Clin Oncol 2003; 21: 2466–2473.

    Article  CAS  PubMed  Google Scholar 

  94. van Besien KW, Mehra RC, Giralt SA, Kantarjian HM, Pugh WC, Khouri IF et al. Allogeneic bone marrow transplantation for poor-prognosis lymphoma: response, toxicity and survival depend on disease histology. Am J Med 1996; 100: 299–307.

    Article  CAS  PubMed  Google Scholar 

  95. Juckett M, Rowlings P, Hessner M, Keever-Taylor C, Burns W, Camitta B et al. T cell-depleted allogeneic bone marrow transplantation for high-risk non-Hodgkin's lymphoma: clinical and molecular follow-up. Bone Marrow Transplant 1998; 21: 893–899.

    Article  CAS  PubMed  Google Scholar 

  96. Shepherd JD, Barnett MJ, Connors JM, Spinelli JJ, Sutherland HJ, Kingemann HG et al. Allogeneic bone marrow transplantation for poor-prognosis non-Hodgkin's lymphoma. Bone Marrow Transplant 1993; 12: 591–596.

    CAS  PubMed  Google Scholar 

  97. Jones RJ, Ambinder RF, Piantadosi S, Santos GW . Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 1991; 77: 649–653.

    CAS  PubMed  Google Scholar 

  98. Peniket A, Ruiz de Elvira MC, Taghipour G . Allogeneic transplantation for lymphoma produces a lower relapse rate than autologous transplantation but survival has not risen because of higher treatment-related mortality-a report of 674 cases from the EBMT lymphoma registry. Blood 1997; 90 (Suppl. 1): 255a.

    Google Scholar 

  99. Schimmer AD, Jamal S, Messner H, Keating A, Meharchand J, Huebsch L et al. Allogeneic or autologous bone marrow transplantation (BMT) for non-Hodgkin's lymphoma (NHL): results of a provincial strategy, Ontario BMT Network, Canada. Bone Marrow Transplant 2000; 26: 859–864.

    Article  CAS  PubMed  Google Scholar 

  100. Mendoza E, Territo M, Schiller G, Lill M, Kunkel L, Wolin M . Allogeneic bone marrow transplantation for Hodgkin's and non-Hodgkin's lymphoma. Bone Marrow Transplant 1995; 15: 299–303.

    CAS  PubMed  Google Scholar 

  101. Dann EJ, Daugherty CK, Larson RA . Allogeneic bone marrow transplantation for relapsed and refractory Hodgkin's disease and non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 20: 369–374.

    Article  CAS  PubMed  Google Scholar 

  102. Appelbaum FR, Sullivan KM, Buckner CD, Clift RA, Deeg HJ, Fefer A et al. Treatment of malignant lymphoma in 100 patients with chemotherapy, total body irradiation, and marrow transplantation. J Clin Oncol 1987; 5: 1340–1347.

    Article  CAS  PubMed  Google Scholar 

  103. Dhedin N, Giraudier S, Gaulard P, Esperou H, Ifrah N, Michallet M et al. Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database. Societ Francaise de Greffe de Moelle. Br J Haematol 1999; 107: 154–161.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hematology/Oncology, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY, USA

    R I Fisher & P Shah

Authors
  1. R I Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fisher, R., Shah, P. Current trends in large cell lymphoma. Leukemia 17, 1948–1960 (2003). https://doi.org/10.1038/sj.leu.2403096

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2403096

Keywords

This article is cited by

Search

Advanced search

Quick links